Market Cap
US$500.8m
Last Updated
2021/04/17 23:19 UTC
Data Sources
Company Financials +
Executive Summary
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. More Details
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has ChromaDex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CDXC is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 31% a week.
Volatility Over Time: CDXC's weekly volatility has increased from 17% to 31% over the past year.
Market Performance
7 Day Return
-13.4%
CDXC
2.2%
US Life Sciences
1.3%
US Market
1 Year Return
119.3%
CDXC
62.3%
US Life Sciences
53.9%
US Market
Return vs Industry: CDXC exceeded the US Life Sciences industry which returned 62.3% over the past year.
Return vs Market: CDXC exceeded the US Market which returned 53.9% over the past year.
Shareholder returns
| CDXC | Industry | Market | |
|---|---|---|---|
| 7 Day | -13.4% | 2.2% | 1.3% |
| 30 Day | -28.9% | 9.2% | 5.3% |
| 90 Day | 75.6% | 2.9% | 8.9% |
| 1 Year | 119.3%119.3% | 62.5%62.3% | 56.6%53.9% |
| 3 Year | 97.6%97.6% | 116.7%115.4% | 64.4%53.6% |
| 5 Year | 80.2%80.2% | 216.1%212.3% | 120.4%95.7% |
Long-Term Price Volatility Vs. Market
How volatile is ChromaDex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Kind Of Investors Own Most Of ChromaDex Corporation (NASDAQ:CDXC)?3 weeks ago | Simply Wall St
ChromaDex Corporation (NASDAQ:CDXC): Is Breakeven Near?1 month ago | Simply Wall St
Have Insiders Sold ChromaDex Corporation (NASDAQ:CDXC) Shares Recently?Valuation
Is ChromaDex undervalued compared to its fair value and its price relative to the market?
17.8%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CDXC ($8.2) is trading below our estimate of fair value ($9.98)
Significantly Below Fair Value: CDXC is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CDXC is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.
PE vs Market: CDXC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CDXC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CDXC is overvalued based on its PB Ratio (30.8x) compared to the US Life Sciences industry average (7.9x).
Future Growth
How is ChromaDex forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
67.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDXC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CDXC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CDXC's is expected to become profitable in the next 3 years.
Revenue vs Market: CDXC's revenue (22.9% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: CDXC's revenue (22.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDXC's Return on Equity is forecast to be high in 3 years time
Past Performance
How has ChromaDex performed over the past 5 years?
-34.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CDXC is currently unprofitable.
Growing Profit Margin: CDXC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CDXC is unprofitable, and losses have increased over the past 5 years at a rate of 34.5% per year.
Accelerating Growth: Unable to compare CDXC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CDXC is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (7.4%).
Return on Equity
High ROE: CDXC has a negative Return on Equity (-121.32%), as it is currently unprofitable.
Financial Health
How is ChromaDex's financial position?
Financial Position Analysis
Short Term Liabilities: CDXC's short term assets ($32.2M) exceed its short term liabilities ($16.5M).
Long Term Liabilities: CDXC's short term assets ($32.2M) exceed its long term liabilities ($5.5M).
Debt to Equity History and Analysis
Debt Level: CDXC is debt free.
Reducing Debt: CDXC has no debt compared to 5 years ago when its debt to equity ratio was 92.4%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CDXC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CDXC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is ChromaDex current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CDXC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CDXC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CDXC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CDXC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CDXC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.5yrs
Average management tenure
CEO
Rob Fried (60 yo)
2.83yrs
Tenure
US$1,711,894
Compensation
Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of ChromaDex Corp. since June 22, 2018 and its a Director since July 2015. Mr. Fried was the Chief Operating Officer of ChromaDe...
CEO Compensation Analysis
Compensation vs Market: Rob's total compensation ($USD1.71M) is about average for companies of similar size in the US market ($USD1.58M).
Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: CDXC's management team is considered experienced (2.5 years average tenure).
Board Members
Experienced Board: CDXC's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CDXC insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.
Top Shareholders
Company Information
ChromaDex Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: ChromaDex Corporation
- Ticker: CDXC
- Exchange: NasdaqCM
- Founded: NaN
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$500.751m
- Shares outstanding: 66.76m
- Website: https://www.chromadex.com
Number of Employees
Location
- ChromaDex Corporation
- 10900 Wilshire Boulevard
- Suite 600
- Los Angeles
- California
- 90024
- United States
Listings
Biography
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Service...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/17 23:19 |
| End of Day Share Price | 2021/04/16 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.